Changeflow GovPing Healthcare & Life Sciences Fc-IL2 variant cancer therapy combination patents
Routine Notice Added Final

Fc-IL2 variant cancer therapy combination patents

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

USPTO published patent application US20260091062A1 by Hoffmann-La Roche Inc. covering recombinant Fc domain-IL-2 variant polypeptides combined with membrane-anchored antigen binding polypeptides for cancer treatment. The application (No. 19272092) was filed July 17, 2025, and published April 2, 2026.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

Hoffmann-La Roche Inc. received USPTO publication for patent application US20260091062A1 covering combination therapy using recombinant Fc domain-IL-2 variant polypeptides with membrane-anchored antigen binding polypeptides for cancer prevention and treatment. The application claims compositions and methods classified under CPC codes including A61K 35/17, C07K 14/55, and C07K 14/705. Inventors include Diana Darowski, Stephan Gasser, Christian Klein, Simone Lang, and Dario Venetz.

This patent publication is informational only and does not impose compliance requirements. Pharmaceutical companies developing IL-2 based cancer immunotherapies should review the claims to assess potential freedom-to-operate considerations. No action is required unless the entity is actively developing competing IL-2 variant therapies that may fall within the claimed combination framework.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

Recombinant Fc domain - IL2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides

Application US20260091062A1 Kind: A1 Apr 02, 2026

Assignee

Hoffmann-La Roche Inc.

Inventors

Diana DAROWSKI, Stephan GASSER, Christian KLEIN, Simone LANG, Dario VENETZ

Abstract

The present invention relates to the combination therapy of recombinant Fc domain-IL-2 variant polypeptides with membrane-anchored antigen binding polypeptides in the prevention or treatment of cancer.

CPC Classifications

A61K 35/17 A61K 40/11 A61K 40/31 A61K 40/4217 A61K 40/4234 A61P 35/00 A61P 37/04 C07K 14/55 C07K 14/7051 C07K 14/70517 C07K 14/70535 C07K 14/7155 C12N 5/0018 A61K 2239/11 C07K 2319/30 C12N 2501/2302 C12N 2501/515

Filing Date

2025-07-17

Application No.

19272092

View original document →

Named provisions

Recombinant Fc domain - IL2 variant polypeptides Combination therapy with membrane-anchored antigen binding polypeptides Prevention or treatment of cancer

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260091062A1 / Application No. 19272092

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing 6211 Healthcare Providers 3254.1 Biotechnology
Activity scope
Biopharmaceutical Patent Applications Cancer Immunotherapy Research IL-2 Variant Development
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Healthcare Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!